A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.
Animals
Mice
BCG Vaccine
/ immunology
Ebolavirus
/ immunology
Hemorrhagic Fever, Ebola
/ prevention & control
Ebola Vaccines
/ immunology
Antibodies, Viral
/ immunology
T-Lymphocytes, Helper-Inducer
/ immunology
Vaccination
/ methods
Mice, Inbred C57BL
Female
Humans
Disease Models, Animal
Receptors, IgG
/ immunology
Vaccine Development
Immunoglobulin Class Switching
Immunization
CD4+ T cells
Ebola virus
Fc receptors
Mycobacterium bovis BCG
antibodies
intrastructural help
vaccines
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
05
2024
accepted:
25
06
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Previous studies have demonstrated the efficacy and feasibility of an anti-viral vaccine strategy that takes advantage of pre-existing CD4
Identifiants
pubmed: 39081315
doi: 10.3389/fimmu.2024.1429909
pmc: PMC11286471
doi:
Substances chimiques
BCG Vaccine
0
Ebola Vaccines
0
Antibodies, Viral
0
Receptors, IgG
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1429909Informations de copyright
Copyright © 2024 Ng, Furuyama, Wirchnianski, Saavedra-Ávila, Johndrow, Chandran, Jacobs, Marzi and Porcelli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.